Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 3

2(33.3%)

6Total

N/A(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04927052Not ApplicableCompleted

A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment

Role: lead

NCT04029545Phase 3Terminated

A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation

Role: lead

NCT04029519Phase 3Completed

A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation

Role: lead

NCT04032977Completed

Safety and Effectiveness of PN40082 for Lip Augmentation

Role: lead

NCT02991040Not ApplicableCompleted

Study to Evaluate Safety and Efficacy of Revanesse® Ultra + vs Revanesse® Ultra for Correction of NLF

Role: lead

NCT02987205Not ApplicableCompleted

Multicenter Double-Blind Randomized Split-Face Study to Evaluate Revanesse® Ultra vs Restylane® for Correction of NLF

Role: lead

NCT02984878Not ApplicableCompleted

Multicenter Study to Evaluate the Safety and Efficacy of Revanesse® Ultra Retreatment

Role: lead

All 7 trials loaded